Skip To Main Content
Kate Rawson on Muck Rack

Kate Rawson

  • Senior Editor, Prevision Policy
  • Executive Director, Lockhart Vaughan Foundation
Baltimore
As seen in: Prevision Policy, Generics Bulletin, HBW Insight, Citeline, Medtech Insight, The Pink Sheet, Friends of Cancer Research
Drug regulation/health policy journalist, downhill skier, cyclist, Mom to two, school choice supporter, library lover, Baltimore believer. Tweets are all me.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kate

Contact Kate, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

National Priority Voucher Program Should Balance Speedy Reviews With Public Trust, Sponsors Say

|
By Kate Rawson
| The Pink Sheet Verified
Industry execs welcomed the NPV pilot, but sponsors cautioned that hyper-fast reviews could hinder trust in the agency’s decisions. The NPV program's quick reviews could hurt public trust in the decisions. (Shutterstock) Key Takeaways Stakeholders want to ensure FDA review speed with the National Priority Voucher program does not impact public trust in FDA decisions.
Open in Who Shared Issue with article?

Beyond Operation TrialBlazer: Congress Sounds Ready To Act On IND Pathways

|
By Kate Rawson
| The Pink Sheet Verified
A House hearing suggests support for legislating new IND review pathways and building on the Operation TrialBlazer initiative, but sponsors could delay agency advice to sponsors. Legislators are embracing HHS' Operation TrialBlazer initiative to restore US leadership in clinical research. (Shutterstock) Key Takeaways House lawmakers appear eager to build on the FDA's plan to expedite IND reviews as part of the upcoming user fee reauthorization, based on comments at a recent hearing.
Open in Who Shared Issue with article?

Pink Sheet — Beyond Operation TrialBlazer: Congress Sounds Ready To Act On IND Pathways

|
By Kate Rawson
| Friends of Cancer Research
Legislators appears eager to build on the US Food and Drug Administration’s plans to expedite IND reviews in the upcoming user fee reauthorization cycle.
Open in Who Shared Issue with article?
See all 200 articles